AXSM Axsome Therapeutics Inc.

14.95
-0.06  -0%
Previous Close 15.01
Open 14.95
Price To Book 498.33
Market Cap 497541307
Shares 33,280,355
Volume 581,867
Short Ratio
Av. Daily Volume 1,144,149

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 top-line data met primary endpoint - April 15, 2019.
AXS-05
Smoking cessation
Phase 2/3 top-line data due 1H 2020.
AXS-05 ADVANCE-1
Agitation in patients with Alzheimer’s disease (AD)
Phase 3 interim efficacy analysis January 9, 2017 recommended trial to discontinue due to futility.
AXS-02 CREATE-1
Complex regional pain syndrome (CRPS)
Phase 3 data due 2Q 2019.
AXS-05 STRIDE-1
Treatment resistant depression
Phase 3 interim efficacy analysis January 9, 2017 recommended trial continue to full enrollment.
AXS-02 COAST-1
Knee Osteoarthritis Associated with Bone Marrow Lesions
Phase 3 top-line data due 1Q 2020.
AXS-07 - MOMENTUM
Migraine
Phase 2 data met primary endpoint - January 7, 2019.
AXS-05 ASCEND
Major Depressive Disorder
Phase 2 trial initiation announced January 30, 2019 with top-line data due 2Q 2019.
AXS-12
Narcolepsy

Latest News

  1. Biotech Stock Roundup: GILD Collaborates on NASH, FCSC Surges on Deal
  2. Axsome's AXS-05 Meets Goal in Phase II Study, Shares Up
  3. Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in Phase 2 Trial in Smoking Cessation
  4. Here's Why Axsome Therapeutics Rocketed 78.8% Higher in March
  5. 3 Stocks That Have More Than Tripled So Far in 2019
  6. Implied Volatility Surging for Axsome Therapeutics (AXSM) Stock Options
  7. 3 Leading Alzheimer's Disease Drugs in Development After Biogen's Aducanumab Flop
  8. Axsome's Depression Drug Gets Breakthrough Therapy Status
  9. 3 Small Biotech Stocks Hitting New Highs
  10. Jim Cramer Weighs In On General Electric, Nio, Sprint And More
  11. Analysts Are Bullish on Axsome Therapeutics in March
  12. UPDATE: Axsome Therapeutics shares soar after FDA grants breakthrough designation to depression drug
  13. Axsome Therapeutics Receives FDA Breakthrough Therapy Designation for AXS-05 for the Treatment of Major Depressive Disorder
  14. Here's Why Axsome Therapeutics' Stock Gained as Much as 22.9% Today
  15. Have Insiders Been Buying Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares This Year?
  16. Harry Boxer: 3 biotech stocks with momentum
  17. Axsome: 4Q Earnings Snapshot
  18. Axsome Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update
  19. 2 Biotech Stocks With Major Incoming Catalysts
  20. Axsome Therapeutics Secures $24 Million Growth Capital Loan Facility Led by Silicon Valley Bank